PTC Therapeutics, Inc. (PTCT) Financial Analysis & Valuation | Quarter Chart
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinica... more
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and comm... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $5.06B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Matthew Klein |
| IPO Date | 2013-06-20 | CAGR | 22.68% |
| Employees | 991 | Website | www.ptcbio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
PTCT chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $5.83B | P/E | -26 | Forward P/E | 25.57 | PEG | — |
| P/S | 2.43 | P/B | -14.82 | P/CF | -80.4 | P/FCF | -32.84 |
| Sales | $1.01B | Sales 1Y | -42.84% | Sales 3Y | 23.21% | Sales 5Y | 113.77% |
| EPS | $-2.33 | EPS 1Y | -108.38% | EPS 3Y | -93.06% | EPS 5Y | -89.66% |
| Sales QoQ | 32.28% | EPS QoQ | -2805.88% | Sales QoQ Avg | 23.45% | EPS QoQ Avg | -990.74% |
| Gross Margin | 47.23% | Operating Margin | 11.52% | Profit Margin | -3.8% | ROCE | 4.69% |
| ROA | -1% | ROE | 22% | Altman Z Score | 0.77 | Piotroski Score | 1 |
| Current Ratio | 3.39 | Quick Ratio | 3.28 | Cash Ratio | 1.36 | Op. CF Ratio | 0.17 |
| Debt/Equity | -4.21 | Debt/Assets | 0.21 | Lt Debt/Equity | -3.77 | Lt Debt/Cap. | 1.36 |
| Intrst Cov. | -11.95 | Inventory Turnover | 1.88 | Asset Turnover | 0.31 | Receivables Turnover | 4.22 |
| Enterprise Value | $5.83B | P/E Ratio | -26 |
| Forward P/E | 25.57 | PEG Ratio | — |
| P/S Ratio | 2.43 | P/B Ratio | -14.82 |
| P/CF Ratio | -80.4 | P/FCF Ratio | -32.84 |
| EPS | $-2.33 | EPS Growth 1Y | -108.38% |
| EPS Growth 3Y | -93.06% | EPS Growth 5Y | -89.66% |
| Revenue Growth 1Y | -42.84% | Gross Margin | 47.23% |
| Operating Margin | 11.52% | Profit Margin | -3.8% |
| ROE | 22% | ROA | -1% |
| ROCE | 4.69% | Current Ratio | 3.39 |
| Quick Ratio | 3.28 | Cash Ratio | 1.36 |
| Debt/Equity | -4.21 | Interest Coverage | -11.95 |
| Altman Z Score | 0.77 | Piotroski Score | 1 |
PTC Therapeutics, Inc. (PTCT) valuation & financials
PTC Therapeutics, Inc. (PTCT) has a market capitalization of $5.06B and trades at a price-to-earnings ratio of -26.0. It operates in the Healthcare sector (Biotechnology).
PTC Therapeutics, Inc.'s revenue grew -42.8% over the last year.
PTC Therapeutics, Inc.'s next earnings report is scheduled for October 29, 2026 after market close (provider scheduled date); analysts estimate EPS of $0.30. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)